Testing Radiation and HER2-targeted Therapy Versus HER2-targeted Therapy Alone for Low-risk HER2-positive Breast Cancer
Purpose
This Phase III trial compares the recurrence-free interval (RFI) among patients with early-stage, low risk HER2+ breast cancer who undergo breast conserving surgery and receive HER2-directed therapy, and are randomized to not receive adjuvant breast radiotherapy versus those who are randomized to receive adjuvant radiotherapy per the standard of care.
Condition
- HER2-positive Breast Cancer
Eligibility
- Eligible Ages
- Over 40 Years
- Eligible Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- The patient or a legally authorized representative must provide study-specific informed consent prior to study entry and, for patients treated in the U.S., authorization permitting release of personal health information. - female and male patients who have undergone breast conserving surgery and completed a minimum of 4 cycles (12 weeks) of neoadjuvant or adjuvant chemotherapy in combination with HER2-targeted therapy. -≥ 40 years of age - ECOG performance status of 0 ,1, or 2/Karnofsky performance status above 60 - Histologically or cytologically confirmed invasive breast carcinoma. - tumor must have been determined to be HER2-positive by current ASCO/CAP guidelines based on local testing results. - Patient must have undergone axillary staging, either sentinel node biopsy (SNB) or axillary lymph nodal dissection (ALND). In neoadjuvant patients, SNB following neoadjuvant therapy is strongly recommended. SNB prior to neoadjuvant therapy is discouraged, but patients are permitted if node negative (pN0). - The following staging criteria must be met according to AJCC 8th edition criteria: Adjuvant cohort : By pathologic evaluation, the patient's primary tumor must be </= 2 cm and ipsilateral nodes must be pN0. Surgical lumpectomy margins must be negative for invasive cancer and ductal carcinoma in situ (no ink on tumor). Neoadjuvant cohort: Prior to neoadjuvant therapy, the patient's primary tumor must be < 3 cm by imaging studies, with negative axillary nodes (cN0) based on axillary U/S, CT, PET or MRI. Physical examination is not sufficient documentation of cN0 status; • Must be ypT0N0 at surgery (lumpectomy); patients with residual non-invasive disease (DCIS) in the surgical specimen (ypTis), are NOT eligible. - For the Adjuvant cohort, adjuvant therapy must have consisted of a minimum of 4 cycles (12 weeks) of chemotherapy in combination with HER2-targeted therapy. - For the Neoadjuvant cohort, neoadjuvant therapy must have consisted of a minimum of 4 cycles (12 weeks) of chemotherapy in combination with HER2-targeted therapy.- ; Patients who did not receive chemotherapy in the neoadjuvant setting are not eligible, even if they achieved pCR with their preoperative treatment; nor would these patients become eligible by receiving chemotherapy after surgery. - In patients assigned to radiation therapy, treatment should start ≤ 12 weeks from surgery on the Neoadjuvant cohort and ≤ 8 weeks from the completion of chemotherapy on the Adjuvant cohort. Patients should continue HER2-targeted therapy during assigned study treatment (radiation or observation). - Bilateral mammogram or MRI within 52 weeks prior to randomization. - HIV-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months of randomization are eligible for this trial.
Exclusion Criteria
- Definitive clinical or radiologic evidence of metastatic disease. - On the Adjuvant cohort, patients with a primary tumor >2 cm on pathologic examination of the surgical specimen. On the Neoadjuvant cohort, patients with a primary tumor > 3 cm or with abnormal or suspicious ipsilateral axillary nodes by pretreatment imaging, unless demonstrated to be negative by cytologic or histologic examination. - Pathologically positive axillary nodes at any time including of pN0(i+) or pN0(mol+) ypN0(i+) or ypN0(mol+) disease. - Patient planning for or status-post mastectomy. - Radiographically suspicious ipsilateral or contralateral axillary, supraclavicular, infraclavicular, or internal mammary lymph nodes, unless there is histological confirmation that these nodes are negative for metastatic disease. - Suspicious microcalcifications, densities, or palpable abnormalities (in the ipsilateral or contralateral breast), or mass or non-mass enhancement on MRI (if performed) aside from the known cancer, unless biopsied and found to be benign. - Non-epithelial breast malignancies such as sarcoma or lymphoma. - Multicentric carcinoma (invasive cancer or DCIS) in more than one quadrant or separated by > 4 centimeters. If multifocal, all foci should be confined to a maximum tumor bed of 3 cm determined by pathological assessment. - Paget's disease of the nipple. - Synchronous (unilateral or bilateral) invasive breast cancer or DCIS. (Patients with synchronous and/or previous contralateral LCIS are eligible.) - On the Adjuvant cohort, surgical margins that cannot be microscopically assessed or are positive at pathologic evaluation. (If surgical margins are rendered free of disease by re-excision, the patient is eligible). - Treatment plan that includes regional nodal irradiation. - Patients treated for a prior invasive breast malignancy are excluded. Contralateral DCIS ≥ 10 years prior to enrollment is permissible. - Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial. - Patients on oral, transdermal, or subdermal estrogen replacement (including all estrogen only and estrogen-progesterone formulas) are not eligible unless discontinued prior to randomization. - Prior ipsilateral breast or thoracic RT for any condition (contralateral RT for DCIS ≥ 10 years prior to randomization is permitted). - Active collagen vascular disease, specifically dermatomyositis with a CPK level above normal or with an active systemic lupus erythematosus, or scleroderma. - Clinicians should consider whether any conditions would make this protocol unreasonably hazardous for the patient. - Pregnancy or lactation at the time of randomization or intention to become pregnant during treatment. (Note: Pregnancy testing according to institutional standards for patients of childbearing potential must be performed within 14 days prior to randomization.) - Use of any investigational product within 30 days prior to randomization.
Study Design
- Phase
- Phase 3
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel Assignment
- Intervention Model Description
- Subjects who are receiving standard of care systemic HER2-targeted therapies are randomized to standard of care adjuvant breast radiation or no breast radiation
- Primary Purpose
- Treatment
- Masking
- None (Open Label)
Arm Groups
| Arm | Description | Assigned Intervention |
|---|---|---|
|
Active Comparator Standard of Care Adjuvant Breast Radiation |
Patients continue to receive their current planned adjuvant breast radiation and systemic HER2-targeted therapies |
|
|
Active Comparator Standard of Care HER2-targeted Therapy Without Adjuvant Breast Radiation |
Patients continue to receive their current systemic HER2-targeted therapy without breast adjuvant radiation |
|
Recruiting Locations
Phoenix 5308655, Arizona 5551752 85004
Tucson 5318313, Arizona 5551752 85719
Tucson 5318313, Arizona 5551752 85719
Jonesboro 4116834, Arkansas 4099753 72401
Antioch 5324200, California 5332921 94531
Arroyo Grande 5324802, California 5332921 93420
Arroyo Grande 5324802, California 5332921 93420
Auburn 5325223, California 5332921 95602
Auburn 5325223, California 5332921 95603
Beverly Hills 5328041, California 5332921 90211
Cameron Park 5333282, California 5332921 95682
Duarte 5344147, California 5332921 91010
Dublin 5344157, California 5332921 94568
Site Public Contact
877-642-4691
Fremont 5350734, California 5332921 94538
Fremont 5350734, California 5332921 94538
Fresno 5350937, California 5332921 93720
Fresno 5350937, California 5332921 93720
Irvine 5359777, California 5332921 92612
Irvine 5359777, California 5332921 92618
Site Public Contact
877-467-3411
Lancaster 5364940, California 5332921 93534
Los Angeles 5368361, California 5332921 90033
Los Angeles 5368361, California 5332921 90033
Site Public Contact
323-865-0451
Los Angeles 5368361, California 5332921 90048
Site Public Contact
310-423-8965
Modesto 5373900, California 5332921 95355
Modesto 5373900, California 5332921 95356
Mountain View 5375480, California 5332921 94040
Oakland 5378538, California 5332921 94611
Oakland 5378538, California 5332921 94611
Orange 5379513, California 5332921 92868
Palo Alto 5380748, California 5332921 94301
Palo Alto 5380748, California 5332921 94304
Pomona 5384170, California 5332921 91767
Site Public Contact
909-865-9555
Rancho Cordova 5385941, California 5332921 95670
Redwood City 5386834, California 5332921 94063
Site Public Contact
877-642-4691
Richmond 5387428, California 5332921 94801
Rohnert Park 5388564, California 5332921 94928
Roseville 5388881, California 5332921 95661
Roseville 5388881, California 5332921 95661
Roseville 5388881, California 5332921 95661
Roseville 5388881, California 5332921 95678
Sacramento 5389489, California 5332921 95814
Sacramento 5389489, California 5332921 95816
Sacramento 5389489, California 5332921 95817
Site Public Contact
916-734-3089
Sacramento 5389489, California 5332921 95823
Sacramento 5389489, California 5332921 95823
San Francisco 5391959, California 5332921 94115
San Francisco 5391959, California 5332921 94115
San Jose 5392171, California 5332921 95119
San Jose 5392171, California 5332921 95124
San Leandro 5392263, California 5332921 94577
San Luis Obispo 5392323, California 5332921 93401
San Rafael 5392567, California 5332921 94903
Santa Barbara 5392952, California 5332921 93105
Santa Clara 5393015, California 5332921 95051
Santa Maria 5393180, California 5332921 93444
Santa Rosa 5393287, California 5332921 95403
Santa Rosa 5393287, California 5332921 95403
South Pasadena 5397717, California 5332921 91030
South San Francisco 5397765, California 5332921 94080
South San Francisco 5397765, California 5332921 94080
Stockton 5399020, California 5332921 95210
Sunnyvale 5400075, California 5332921 94086
Tarzana 5401143, California 5332921 91356
Site Public Contact
818-981-3818
Torrance 5403022, California 5332921 90503
Site Public Contact
877-467-3411
Torrance 5403022, California 5332921 90505
Upland 5404915, California 5332921 91786
Vacaville 5405228, California 5332921 95688
Vallejo 5405380, California 5332921 94589
Walnut Creek 5406990, California 5332921 94596
Aurora 5412347, Colorado 5417618 80045
Site Public Contact
720-848-0650
Colorado Springs 5417598, Colorado 5417618 80907
Colorado Springs 5417598, Colorado 5417618 80907
Colorado Springs 5417598, Colorado 5417618 80909
Site Public Contact
719-365-2406
Colorado Springs 5417598, Colorado 5417618 80920
Site Public Contact
719-364-6700
Colorado Springs 5417598, Colorado 5417618 80923
Fort Collins 5577147, Colorado 5417618 80524
Site Public Contact
970-297-6150
Fort Collins 5577147, Colorado 5417618 80528
Greeley 5577592, Colorado 5417618 80631
Highlands Ranch 5425043, Colorado 5417618 80129
Site Public Contact
720-848-0650
Loveland 5579368, Colorado 5417618 80538
Site Public Contact
970-203-7083
Atlantis 4146372, Florida 4155751 33462
Site Public Contact
561-964-2662
Clearwater 4151316, Florida 4155751 33756
Site Public Contact
855-314-8646
Fort Myers 4155995, Florida 4155751 33901
Site Public Contact
877-680-0008
Fort Myers 4155995, Florida 4155751 33905
N. Venice, Florida 4155751 34275
Site Public Contact
941-261-9000
Plantation 4168782, Florida 4155751 33324
Sarasota 4172131, Florida 4155751 34232
Sarasota 4172131, Florida 4155751 34232
Site Public Contact
941-200-1125
Sarasota 4172131, Florida 4155751 34236
Site Public Contact
941-957-1000
Sarasota 4172131, Florida 4155751 34239
Site Public Contact
941-917-5400
Sarasota 4172131, Florida 4155751 34239
Site Public Contact
941-917-8383
Sarasota 4172131, Florida 4155751 34239
Site Public Contact
941-917-2225
Sarasota 4172131, Florida 4155751 34243
Site Public Contact
941-917-6519
Tampa 4174757, Florida 4155751 33607
Tampa 4174757, Florida 4155751 33612
Tampa 4174757, Florida 4155751 33612
Venice 4176380, Florida 4155751 34275
Venice 4176380, Florida 4155751 34285
Wesley Chapel 4177727, Florida 4155751 33544
Atlanta 4180439, Georgia 4197000 30303
Site Public Contact
404-778-1868
Atlanta 4180439, Georgia 4197000 30308
Atlanta 4180439, Georgia 4197000 30308
Site Public Contact
888-946-7447
Atlanta 4180439, Georgia 4197000 30322
Site Public Contact
404-778-1868
Atlanta 4180439, Georgia 4197000 30342
Site Public Contact
404-851-7115
Decatur 4191124, Georgia 4197000 30033
Johns Creek 6331909, Georgia 4197000 30097
Newnan 4212684, Georgia 4197000 30265
Site Public Contact
770-400-6629
Valdosta 4228147, Georgia 4197000 31602
Honolulu 5856195, Hawaii 5855797 96813
Honolulu 5856195, Hawaii 5855797 96813
Site Public Contact
808-532-0315
Honolulu 5856195, Hawaii 5855797 96813
Site Public Contact
808-545-8548
Honolulu 5856195, Hawaii 5855797 96813
Site Public Contact
808-522-4333
Honolulu 5856195, Hawaii 5855797 96813
Site Public Contact
808-586-2979
Honolulu 5856195, Hawaii 5855797 96817
Site Public Contact
808-547-9816
Honolulu 5856195, Hawaii 5855797 96817
Site Public Contact
808-531-8521
Honolulu 5856195, Hawaii 5855797 96826
Site Public Contact
808-983-6090
Kailua 5847486, Hawaii 5855797 96734
Lihue 5850248, Hawaii 5855797 96766
Site Public Contact
808-535-7960
‘Aiea 5856430, Hawaii 5855797 96701
‘Aiea 5856430, Hawaii 5855797 96701
Site Public Contact
808-486-6000
‘Aiea 5856430, Hawaii 5855797 96701
Site Public Contact
808-487-7447
‘Aiea 5856430, Hawaii 5855797 96701
Site Public Contact
808-678-9000
‘Ewa Beach 5855051, Hawaii 5855797 96706
Boise 5586437, Idaho 5596512 83712
Fruitland 5593708, Idaho 5596512 83619
Meridian 5600685, Idaho 5596512 83642
Nampa 5601933, Idaho 5596512 83687
Twin Falls 5610810, Idaho 5596512 83301
Aurora 4883817, Illinois 4896861 60504
Centralia 4235587, Illinois 4896861 62801
Chicago 4887398, Illinois 4896861 60611
Chicago 4887398, Illinois 4896861 60612
Site Public Contact
312-864-5204
Chicago 4887398, Illinois 4896861 60637
Danville 4889426, Illinois 4896861 61832
Decatur 4236895, Illinois 4896861 62526
Decatur 4236895, Illinois 4896861 62526
DeKalb 4889553, Illinois 4896861 60115
Effingham 4237727, Illinois 4896861 62401
Effingham 4237727, Illinois 4896861 62401
Elmhurst 4891010, Illinois 4896861 60126
Geneva 4893591, Illinois 4896861 60134
Glenview 4893886, Illinois 4896861 60026
Site Public Contact
312-695-1102
Grayslake 4894465, Illinois 4896861 60030
Site Public Contact
312-695-1102
Harvey 4895298, Illinois 4896861 60426
Lake Forest 4899012, Illinois 4896861 60045
Mattoon 4244099, Illinois 4896861 61938
Maywood 4901514, Illinois 4896861 60153
Site Public Contact
708-226-4357
Naperville 4903279, Illinois 4896861 60540
Site Public Contact
630-646-6075
New Lenox 4903535, Illinois 4896861 60451
Normal 4903780, Illinois 4896861 61761
O'Fallon 4245926, Illinois 4896861 62269
O'Fallon 4245926, Illinois 4896861 62269
Orland Park 4904937, Illinois 4896861 60462
Orland Park 4904937, Illinois 4896861 60462
Springfield 4250542, Illinois 4896861 62702
Site Public Contact
217-545-7929
Springfield 4250542, Illinois 4896861 62702
Site Public Contact
800-444-7541
Springfield 4250542, Illinois 4896861 62781
Urbana 4914570, Illinois 4896861 61801
Warrenville 4915525, Illinois 4896861 60555
Zion 4917358, Illinois 4896861 60099
Site Public Contact
844-793-0745
Crown Point 4919451, Indiana 4921868 46307
Site Public Contact
219-310-2550
Crown Point 4919451, Indiana 4921868 46307
Dyer 4919820, Indiana 4921868 46311
Site Public Contact
219-924-8178
Goshen 4920808, Indiana 4921868 46526
Hobart 4921476, Indiana 4921868 46342
Site Public Contact
219-947-1795
Hobart 4921476, Indiana 4921868 46342
Munster 4924014, Indiana 4921868 46321
Site Public Contact
219-836-3349
Munster 4924014, Indiana 4921868 46321
Richmond 4263681, Indiana 4921868 47374
Valparaiso 4927537, Indiana 4921868 46383
Ames 4846834, Iowa 4862182 50010
Site Public Contact
515-956-4132
Ames 4846834, Iowa 4862182 50010
Ankeny 4846960, Iowa 4862182 50023
Site Public Contact
515-241-3305
Cedar Rapids 4850751, Iowa 4862182 52402
Site Public Contact
319-297-2900
Clive 4852065, Iowa 4862182 50325
Clive 4852065, Iowa 4862182 50325
Site Public Contact
515-241-3305
Creston 4853078, Iowa 4862182 50801
Des Moines 4853828, Iowa 4862182 50309
Site Public Contact
515-241-6727
Des Moines 4853828, Iowa 4862182 50309
Site Public Contact
515-241-3305
Des Moines 4853828, Iowa 4862182 50314
Des Moines 4853828, Iowa 4862182 50314
Site Public Contact
515-241-3305
Waukee 4880981, Iowa 4862182 50263
Site Public Contact
515-241-3305
West Des Moines 4881346, Iowa 4862182 50266
Kansas City 4273837, Kansas 4273857 66160
Olathe 4276614, Kansas 4273857 66061
Overland Park 4276873, Kansas 4273857 66210
Overland Park 4276873, Kansas 4273857 66211
Salina 4278890, Kansas 4273857 67401
Topeka 4280539, Kansas 4273857 66606
Site Public Contact
785-295-8000
Westwood 4281639, Kansas 4273857 66205
Louisville 4299276, Kentucky 6254925 40202
Site Public Contact
502-562-3429
Louisville 4299276, Kentucky 6254925 40245
Baltimore 4347778, Maryland 4361885 21201
Site Public Contact
800-888-8823
Bel Air 4348240, Maryland 4361885 21014
Site Public Contact
443-643-3010
Columbia 4352053, Maryland 4361885 21044
Site Public Contact
443-546-1300
Easton 4353962, Maryland 4361885 21601
Glen Burnie 4356188, Maryland 4361885 21061
Site Public Contact
410-553-8100
Largo 4360345, Maryland 4361885 20774
Battle Creek 4985153, Michigan 5001836 49017
Brownstown, Michigan 5001836 48183
Clarkston 4988997, Michigan 5001836 48346
Clinton Township 4989133, Michigan 5001836 48038
Dearborn 4990510, Michigan 5001836 48126
Detroit 4990729, Michigan 5001836 48202
Escanaba 4992232, Michigan 5001836 49829
Farmington Hills 4992523, Michigan 5001836 48334
Flint 4992982, Michigan 5001836 48503
Flint 4992982, Michigan 5001836 48503
Grand Rapids 4994358, Michigan 5001836 49503
Grand Rapids 4994358, Michigan 5001836 49503
Grand Rapids 4994358, Michigan 5001836 49503
Jackson 4997384, Michigan 5001836 49201
Macomb 5000473, Michigan 5001836 48044
Madison Heights 5000500, Michigan 5001836 48071
Novi 5004062, Michigan 5001836 48377
Pontiac 5006166, Michigan 5001836 48341
Royal Oak 5007804, Michigan 5001836 48073
Site Public Contact
248-551-7695
Saginaw 5007989, Michigan 5001836 48601
Tawas City 5011900, Michigan 5001836 48764
Troy 5012639, Michigan 5001836 48085
Site Public Contact
248-551-7695
Troy 5012639, Michigan 5001836 48098
West Bloomfield 7259621, Michigan 5001836 48322
Wyoming 5015618, Michigan 5001836 49519
Bemidji 5017822, Minnesota 5037779 56601
Brainerd 5019116, Minnesota 5037779 56401
Coon Rapids 5022025, Minnesota 5037779 55433
Deer River 5024099, Minnesota 5037779 56636
Duluth 5024719, Minnesota 5037779 55805
Duluth 5024719, Minnesota 5037779 55805
Duluth 5024719, Minnesota 5037779 55805
Duluth 5024719, Minnesota 5037779 55805
Edina 5025264, Minnesota 5037779 55435
Hibbing 5030005, Minnesota 5037779 55746
Site Public Contact
218-786-3308
Minneapolis 5037649, Minnesota 5037779 55407
Monticello 5038045, Minnesota 5037779 55362
Saint Cloud 5044407, Minnesota 5037779 56303
Saint Paul 5045360, Minnesota 5037779 55101
Saint Paul 5045360, Minnesota 5037779 55102
Sandstone 5045908, Minnesota 5037779 55072
Shakopee 5046997, Minnesota 5037779 55379
Stillwater 5048814, Minnesota 5037779 55082
Virginia 5051468, Minnesota 5037779 55792
Waconia 5051640, Minnesota 5037779 55387
Columbus 4422442, Mississippi 4436296 39705
Grenada 4428539, Mississippi 4436296 38901
New Albany 4438121, Mississippi 4436296 38652
Oxford 4440076, Mississippi 4436296 38655
Southhaven 4446702, Mississippi 4436296 38671
Cape Girardeau 4379966, Missouri 4398678 63703
Farmington 4386289, Missouri 4398678 63640
Site Public Contact
314-996-5569
Kansas City 4393217, Missouri 4398678 64154
Lee's Summit 4394870, Missouri 4398678 64064
North Kansas City 4400860, Missouri 4398678 64116
Sainte Genevieve 4407294, Missouri 4398678 63670
Site Public Contact
314-996-5569
Springfield 4409896, Missouri 4398678 65804
Site Public Contact
417-269-4520
St Louis 4407066, Missouri 4398678 63128
St Louis 4407066, Missouri 4398678 63131
Site Public Contact
314-996-5569
St Louis 4407066, Missouri 4398678 63141
Site Public Contact
314-251-7066
Sullivan 4410669, Missouri 4398678 63080
Site Public Contact
314-996-5569
Sunset Hills 4410836, Missouri 4398678 63127
Site Public Contact
314-996-5569
Billings 5640350, Montana 5667009 59101
Bozeman 5641727, Montana 5667009 59715
Bellevue 5063805, Nebraska 5073708 68123
Kearney 5071348, Nebraska 5073708 68847
Lincoln 5072006, Nebraska 5073708 68516
Omaha 5074472, Nebraska 5073708 68118
Site Public Contact
402-559-5600
Omaha 5074472, Nebraska 5073708 68198
Henderson 5505411, Nevada 5509151 89052
Las Vegas 5506956, Nevada 5509151 89102
Las Vegas 5506956, Nevada 5509151 89106
Las Vegas 5506956, Nevada 5509151 89119
Las Vegas 5506956, Nevada 5509151 89128
Las Vegas 5506956, Nevada 5509151 89135
Las Vegas 5506956, Nevada 5509151 89144
Las Vegas 5506956, Nevada 5509151 89148
Las Vegas 5506956, Nevada 5509151 89148
Lebanon 5088597, New Hampshire 5090174 03756
Basking Ridge 5095409, New Jersey 5101760 07920
Site Public Contact
212-639-7592
Middletown 5101170, New Jersey 5101760 07748
Site Public Contact
212-639-7592
Montvale 5101361, New Jersey 5101760 07645
Site Public Contact
212-639-7592
Bay Shore 5108169, New York 5128638 11706
Site Public Contact
516-734-8896
Canandaigua 5111405, New York 5128638 14424
Site Public Contact
585-396-6161
Commack 5113412, New York 5128638 11725
Site Public Contact
212-639-7592
Dansville 5114492, New York 5128638 14437
Greenlawn 5119377, New York 5128638 11740
Site Public Contact
516-734-8896
Harrison 5120095, New York 5128638 10604
Site Public Contact
212-639-7592
Lake Success 5123853, New York 5128638 11042
Site Public Contact
516-734-8896
Mount Kisco 5127744, New York 5128638 10549
New York 5128581, New York 5128638 10065
Site Public Contact
212-639-7592
Oswego 5130081, New York 5128638 13126
Rochester 5134086, New York 5128638 14606
Site Public Contact
585-758-7877
Rochester 5134086, New York 5128638 14620
Site Public Contact
585-341-8113
Rochester 5134086, New York 5128638 14623
Rochester 5134086, New York 5128638 14642
Site Public Contact
585-275-5830
Sleepy Hollow 5138371, New York 5128638 10591
Site Public Contact
914-366-1600
Staten Island 5139568, New York 5128638 10305
Site Public Contact
718-226-8888
Stony Brook 5139865, New York 5128638 11794
Site Public Contact
800-862-2215
Syracuse 5140405, New York 5128638 13210
Site Public Contact
315-464-5476
Syracuse 5140405, New York 5128638 13215
Site Public Contact
315-464-5476
The Bronx 5110266, New York 5128638 10461
The Bronx 5110266, New York 5128638 10461
The Bronx 5110266, New York 5128638 10467
Uniondale 5141927, New York 5128638 11553
Site Public Contact
212-639-7592
Verona 5142333, New York 5128638 13478
Webster 5143495, New York 5128638 14580
Greenville 4469160, North Carolina 4482348 27834
Bismarck 5688025, North Dakota 5690763 58501
Fargo 5059163, North Dakota 5690763 58122
Fargo 5059163, North Dakota 5690763 58122
Beavercreek 4506008, Ohio 5165418 45431
Canton 5149222, Ohio 5165418 44708
Site Public Contact
888-293-4673
Centerville 4508204, Ohio 5165418 45459
Centerville 4508204, Ohio 5165418 45459
Columbus 4509177, Ohio 5165418 43210
Columbus 4509177, Ohio 5165418 43214
Columbus 4509177, Ohio 5165418 43215
Columbus 4509177, Ohio 5165418 43228
Dayton 4509884, Ohio 5165418 45409
Dayton 4509884, Ohio 5165418 45409
Site Public Contact
937-276-8320
Dayton 4509884, Ohio 5165418 45415
Dayton 4509884, Ohio 5165418 45415
Delaware 5151891, Ohio 5165418 43015
Delaware 5151891, Ohio 5165418 43015
Dublin 5152333, Ohio 5165418 43016
Franklin 4512203, Ohio 5165418 45005-1066
Franklin 4512203, Ohio 5165418 45005
Greenville 5156493, Ohio 5165418 45331
Site Public Contact
937-569-7515
Kettering 4515843, Ohio 5165418 45429
Mansfield 5161723, Ohio 5165418 44903
Marion 5161902, Ohio 5165418 43302
Troy 5174358, Ohio 5165418 45373
Troy 5174358, Ohio 5165418 45373
Oklahoma City 4544349, Oklahoma 4544379 73104
Oklahoma City 4544349, Oklahoma 4544379 73120
Site Public Contact
405-752-3402
Bend 5713587, Oregon 5744337 97701
Clackamas 5719308, Oregon 5744337 97015
Gresham 5729485, Oregon 5744337 97030
Site Public Contact
503-413-2150
Newberg 5742726, Oregon 5744337 97132
Oregon City 5744253, Oregon 5744337 97045
Portland 5746545, Oregon 5744337 97210
Portland 5746545, Oregon 5744337 97213
Portland 5746545, Oregon 5744337 97225
Tualatin 5757506, Oregon 5744337 97062
Site Public Contact
503-413-1742
Hershey 5193342, Pennsylvania 6254927 17033-0850
Pittsburgh 5206379, Pennsylvania 6254927 15213
Site Public Contact
412-647-2811
Providence 5224151, Rhode Island 5224323 02905
Site Public Contact
401-274-1122
Warwick 5225507, Rhode Island 5224323 02886
Site Public Contact
401-737-7010
Charleston 4574324, South Carolina 4597040 29425
West Columbia 4600541, South Carolina 4597040 29169
Sioux Falls 5231851, South Dakota 5769223 57104
Sioux Falls 5231851, South Dakota 5769223 57117-5134
Collierville 4614748, Tennessee 4662168 38017
Memphis 4641239, Tennessee 4662168 38120
Conroe 4682991, Texas 4736286 77384
Houston 4699066, Texas 4736286 77030
Houston 4699066, Texas 4736286 77079
League City 4705692, Texas 4736286 77573
Sugar Land 4734825, Texas 4736286 77478
Farmington 5774662, Utah 5549030 84025
Salt Lake City 5780993, Utah 5549030 84106
Salt Lake City 5780993, Utah 5549030 84112
Burlington 5234372, Vermont 5242283 05401
Burlington 5234372, Vermont 5242283 05405
Saint Johnsbury 5240656, Vermont 5242283 05819
Mechanicsville 4772566, Virginia 6254928 23116
Midlothian 4772943, Virginia 6254928 23114
Richmond 4781708, Virginia 6254928 23226
Richmond 4781708, Virginia 6254928 23230
Edmonds 5793427, Washington 5815135 98026
Issaquah 5798487, Washington 5815135 98029
Kennewick 5799610, Washington 5815135 99336
Mount Vernon 5804127, Washington 5815135 98274
Seattle 5809844, Washington 5815135 98107
Seattle 5809844, Washington 5815135 98122
Vancouver 5814616, Washington 5815135 98684
Vancouver 5814616, Washington 5815135 98686
Site Public Contact
503-413-2150
Antigo 5244010, Wisconsin 5279468 54409
Ashland 5244247, Wisconsin 5279468 54806
Ashland 5244247, Wisconsin 5279468 54806
Green Bay 5254962, Wisconsin 5279468 54301
Hayward 5255882, Wisconsin 5279468 54843
Menomonee Falls 5262630, Wisconsin 5279468 53051
Site Public Contact
262-257-5100
Milwaukee 5263045, Wisconsin 5279468 53226
Site Public Contact
414-805-3666
Mukwonago 5263965, Wisconsin 5279468 53149
New Richmond 5264475, Wisconsin 5279468 54017
Oak Creek 5265228, Wisconsin 5279468 53154
Site Public Contact
414-805-0505
Oconomowoc 5265499, Wisconsin 5279468 53066
Site Public Contact
262-928-7878
Rhinelander 5268720, Wisconsin 5279468 54501
Sheboygan 5272893, Wisconsin 5279468 53081
Sheboygan 5272893, Wisconsin 5279468 53081
Spooner 5274034, Wisconsin 5279468 54801
Stevens Point 5274644, Wisconsin 5279468 54481
Sturgeon Bay 5274867, Wisconsin 5279468 54235-1495
Superior 5275191, Wisconsin 5279468 54880
Site Public Contact
701-364-6272
Waukesha 5278052, Wisconsin 5279468 53188
Wausau 5278120, Wisconsin 5279468 54401
Site Public Contact
877-405-6866
West Bend 5278422, Wisconsin 5279468 53095
Site Public Contact
414-805-0505
Wisconsin Rapids 5279436, Wisconsin 5279468 54494
Site Public Contact
715-422-7718
Bayamón 4562831, Puerto Rico 00959-5060
Site Public Contact
787-395-7085
Manatí 4566137, Puerto Rico 00674
Site Public Contact
787-621-4397
San Juan 4568127, Puerto Rico 00917
Site Public Contact
787-274-3387
San Juan 4568127, Puerto Rico 00927
San Juan 4568127, Puerto Rico 00936
Site Public Contact
787-763-1296
More Details
- NCT ID
- NCT05705401
- Status
- Recruiting
- Sponsor
- NRG Oncology
Detailed Description
The landmark trials that established breast conservation therapy (BCT) (breast-conserving surgery followed by adjuvant breast irradiation) as a suitable alternative to mastectomy were conducted in an era that predated biological subtyping of breast cancer and the use of HER2-directed therapies in patients with HER2+ cancers. These trials established adjuvant radiotherapy following breast-conserving surgery as necessary to maximize local control, yet, in the intervening years, overall outcomes have improved significantly owing to widespread adoption of screening mammography, resulting in a substantial reduction in average tumor size at diagnosis, as well as improvements in surgical techniques and, crucial for this proposal, the development of highly active systemic therapies. Before the development of HER2-targeted therapies, patients with HER2-driven localized breast cancer had among the highest rates of local recurrence. However, with improved identification of these patients and the advent of HER2-directed therapies, outcomes have improved significantly, and trials have sought to optimize treatment to reduce the morbidity of both local and systemic treatment. Among the most salient of these examples is the APT trial, a single-arm adjuvant study that enrolled 410 breast cancer patients with HER2+ tumors ≤ 3cm in size and negative axillary nodes, who received adjuvant systemic therapy with weekly paclitaxel and trastuzumab for 12 weeks (TH) followed by 9 months of trastuzumab monotherapy. In addition to demonstrating a very low incidence of distant recurrence, among those on the trial who underwent BCT (lumpectomy and radiation, n = 244), only 2 local recurrence (LR) events have been reported after 7 years of follow-up (7-year LR = 1.2%), representing among the most favorable local outcomes of any breast cancer cohort studied to date. Confirmatory results are forthcoming from the ATEMPT trial, which evaluated the antibody-drug conjugate T-DM1 (ado-trastuzumab emtansine) (n=383) vs the TH regimen from the APT trial (n = 114), thus far showing only 3 LRs in each arm with a median 3-years of follow-up. Importantly, per the current standard of care for HER2+ patients undergoing BCT, all patients presumably received adjuvant breast radiotherapy. The balance of the BCT literature, including a landmark meta-analysis by the Early Breast Cancer Trialists' Collaborative Group, suggests that adjuvant radiotherapy approximately halves the risk of local recurrence following lumpectomy across all analyzable subgroups. While the relative benefit appears constant across subgroups, the absolute benefit of adjuvant radiotherapy varies with the underlying risk. Taking the favorable results of the APT trial (1.2% 7-year LR), if one presumes that omission of radiotherapy yields a doubling or tripling of local recurrence (based on the observed RR of 0.5 - 0.66 for those receiving radiotherapy across the preponderance of historical trials), this population might have manifested a LR rate of 2.4 - 3.6% with the omission of radiotherapy. That is to say, the hypothesis is that administration of RT to APT patients undergoing BCT may have reduced the 7-year absolute risk of LR by only 1.2-2.4%. Through the identification of patients who are at low risk of LR, it may be acceptable for such patients to forego radiation. This hypothesis will be studied by evaluating omission of radiotherapy among patients with pT1N0 disease at breast-conserving surgery who receive adjuvant HER2-directed therapy (trastuzumab/paclitaxel preferred, other options per protocol), or with clinical tumors ≤ 3 cm and clinically negative axillary nodes (cN0) who achieve a pathologic complete response (pCR; ypT0N0) following preoperative (neoadjuvant) administration of HER2-directed therapy (trastuzumab/paclitaxel preferred, other options per protocol). It is expcted that the 5-year LR rate for this population omitting radiotherapy will be 2% or less, and that omission of radiation will not have a measurable impact on regional and distant recurrences or overall survival. The practice of breast radiation oncology has benefited immensely from practice-changing trials that have refined the application of adjuvant radiotherapy since the early surgical studies determined whole breast radiotherapy to be necessary following lumpectomy. There are now several favorable breast cancer subtypes in which patients routinely forego radiotherapy after trials demonstrating modest benefits in terms of local recurrence and no impact on distant recurrence or survival, such as among small, low grade luminal cancers in older women and "good-risk" DCIS. Therefore, this will study the omission of radiotherapy among a population of HER2+ breast cancer patients who are now appreciated to also have favorable risk, so as to similarly weigh the attendant inconveniences, cost and morbidity of radiotherapy in light of an established absolute benefit, which may prove to be modest.